Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

NAD+ vs SLU-PP-332: what the research compares

A research-supply comparison of NAD+ and SLU-PP-332: what each compound is, what published work measured, where the evidence is stronger, and what remains unknown.

peptides-pro Editorial

NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme, oxidised form, that functions as an electron carrier in redox reactions and as a substrate for sirtuins, PARPs and CD38; it is not a receptor ligand and has no single defined receptor family. SLU-PP-332 is a small synthetic agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ, described in the literature as a pan-ERR agonist and an exercise mimetic chemical probe [1][2].

The published work on SLU-PP-332 centres on the orphan nuclear receptor family ERRα/β/γ and its downstream transcriptional control of mitochondrial metabolism and exercise-responsive gene programmes [2][7][11].

Research Studies

SLU-PP-332 and ERRα/β/γ agonism in cell-based assays

The first comprehensive structure-activity relationship analysis of the SLU-PP-332 scaffold integrated chemical synthesis, cell-based functional assays and downstream gene-expression profiling, with the stated aim of clarifying the structural features governing potency, efficacy, selectivity and drug-like properties [2]. The same report frames ERRs as master regulators of mitochondrial metabolism and exercise-responsive transcription, and notes that only a limited number of synthetic agonists with suitable potency and drug-like properties had been reported at the time of writing [2].

SLU-PP-332 and analytical detection in anti-doping research

SLU-PP-332 and SLU-PP-915 were characterised by liquid chromatography–high resolution (tandem) mass spectrometry (LC-HRMS/MS), and in vitro metabolic transformation products of both compounds were prepared using human liver S9 fractions [1]. The stated rationale was that ERR agonists under investigation as exercise mimetics could be relevant to sports drug testing programmes [1]. A separate analysis and identification study of in vitro metabolites of SLU-PP-332, an ERRα/β/γ agonist, was conducted for doping-control purposes; that work reports that exercise mimetics mimic physical activity and that WADA prohibits exercise mimetics and metabolic modulators in sport [9].

SLU-PP-332 and ERR activation in human myoblasts from inactive women

A pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women, assessing metabolic and expression changes associated with ERR activation [7]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [7]. The introduction to that study describes ERRs as a potential therapeutic target to counteract muscle decline associated with aging or inactivity, on the basis that they regulate mitochondrial function and cellular respiration by up-regulating key factors in muscle responses to exercise [7].

SLU-PP-915 and aerobic exercise capacity

A report on the orally active ERR agonist SLU-PP-915 describes enhancement of aerobic exercise capacity, and states that ERRα, ERRβ and ERRγ are orphan nuclear receptors regulating genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle, and that ERRs are essential for skeletal muscle adaptation to aerobic exercise [12]. This is a related scaffold rather than SLU-PP-332 itself, and is included here because the two compounds are frequently characterised together in the analytical literature [1].

NAD+ and nicotinamide in retinal protection: the NADIR trial

The NADIR trial is a clinical trial designed to learn whether a high-dose vitamin B3 supplement, nicotinamide, can protect retinal nerve cells in adults with primary open-angle glaucoma who are already receiving standard glaucoma eye drops or laser treatment [3]. The main question it aims to answer is whether adding nicotinamide to standard glaucoma therapy slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, compared with standard therapy alone over 12 months [3]. Participants are randomly assigned to one of two groups, with the treatment group taking nicotinamide tablets by mouth starting at a lower dose of 1.5 grams per day [3]. This is a trial of nicotinamide, an NAD+ precursor, not of NAD+ itself, and it is a study in a glaucoma population.

NAD+ precursor nicotinamide in post-COVID syndrome

An observational study of CICR-NAM, a food for special medicinal purposes, is being conducted in patients with post-COVID syndrome [4]. The background given states that in post-COVID syndrome, changes in tryptophan metabolism, energy metabolism and the gut microbiome may occur, and that in an earlier nutritional study patients with COVID-19 recovered physical performance more quickly when taking nicotinamide, with responders developing post-COVID syndrome less frequently [4]. The tablets were developed at the University Hospital Schleswig-Holstein in Kiel to release the active substance selectively in the lower intestine and are described as well tolerated in several studies [4].

Where the two compounds are compared directly

No study in the evidence block places NAD+ and SLU-PP-332 in the same experiment, the same model or the same outcome measure. The comparison below is therefore a comparison of evidence types, not of head-to-head results.

FeatureNAD+ (and nicotinamide, an NAD+ precursor)SLU-PP-332
ClassDinucleotide coenzyme; nicotinamide is a vitamin B3 formSynthetic small-molecule pan-ERR agonist; exercise mimetic chemical probe [1][2]
Molecular target described in the evidenceNo receptor family named; trials concern retinal nerve cells and post-COVID syndrome [3][4]ERRα, ERRβ, ERRγ orphan nuclear receptors [2][7][11]
Human trial evidence in this blockYes — a randomised trial in primary open-angle glaucoma [3]; an observational study in post-COVID syndrome [4]No human trial in this block; human myoblasts from inactive women were studied ex vivo [7]
Analytical / metabolism dataNot addressed in this blockLC-HRMS/MS characterisation and human liver S9 in vitro metabolites [1]; in vitro metabolite identification for doping control [9]
Structure-activity dataNot addressed in this blockFirst comprehensive SAR analysis of the scaffold reported [2]
Regulatory context notedNot addressed in this blockWADA prohibits exercise mimetics and metabolic modulators in sport [9]

Where the evidence is stronger for each

For NAD+ precursors, the stronger evidence in this block is clinical: a randomised trial with a pre-specified primary outcome in a defined patient population [3], and an observational study in a defined post-COVID population [4]. Both are studies of nicotinamide in people with a diagnosed condition, and neither reports an outcome in healthy adults.

For SLU-PP-332, the stronger evidence in this block is mechanistic and analytical: a systematic SAR analysis linking scaffold structure to potency, efficacy and selectivity [2], mass-spectrometric characterisation with in vitro metabolite identification in human liver fractions [1][9], and ex vivo work in human myoblasts stratified by self-reported activity [7]. The receptor-level rationale is set out in a review of pharmacological ERRα/β/γ activation as an exercise mimetic [11].

What is simply not known

  • No head-to-head study of NAD+ and SLU-PP-332 appears in this evidence block, on any endpoint.
  • No human trial of SLU-PP-332 appears in this block; the human-derived data are from isolated myoblasts [7].
  • No clinical outcome data for NAD+ itself, as distinct from the precursor nicotinamide, appear in this block.
  • The evidence block does not report comparative potency, bioavailability, or duration of effect for either compound.
  • Long-term safety data are not reported for either compound in this block.

Related ERR and metabolic literature in this block

Two further reports are relevant to the ERR axis but do not concern SLU-PP-332 directly. A review of pharmacological ERRα/β/γ activation as an exercise mimetic states that physical inactivity contributes to the development of chronic diseases and that activation of these orphan nuclear receptors has emerged as a molecular strategy to mimic exercise-induced benefits [11]. A study of Guizhi Wuling Decoction reports that the formula has been clinically applied for cardiovascular diseases and that previous studies reported cardioprotective and anti-fibrotic effects, with the work addressing mitochondrial homeostasis [10]. Neither provides data on NAD+ or on SLU-PP-332.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp